论文部分内容阅读
目的观察微生态制剂(双歧杆菌三联活菌+乳果糖)长期应用对肝硬化患者常见并发症的影响。方法 121例乙型肝炎肝硬化患者,随机分为对照组(59例)和治疗组(62例)。对照组给予抗病毒,保肝降酶、利尿、蛋白等营养支持的综合治疗,治疗组在护肝的综合治疗基础上给予双歧杆菌三联活菌片联合乳果糖口服溶液治疗。比较两组肝性脑病、上消化道出血、自发性腹膜炎发生情况及腹水消失情况。结果治疗组肝性脑病、自发性腹膜炎发生率及腹水消失率(12.9%、24.2%、79.0%)均优于对照组(32.2%、45.8%、61.0%),差异均具有统计学意义(P<0.05);两组上消化道出血发生率比较差异无统计学意义(P>0.05)。结论微生态制剂长期应用能有效改善肝硬化症状,减少腹水的产生、降低自发性腹膜炎及肝性脑病的发生率,但对上消化道出血的影响有待进一步研究,此法与普通综合治疗有明显差异,是值得推广的临床治疗方法。
Objective To observe the long-term use of probiotics (Bifidobacterium triple viable lactulose) on the common complications of patients with liver cirrhosis. Methods 121 cases of hepatitis B cirrhosis were randomly divided into control group (59 cases) and treatment group (62 cases). The control group was given comprehensive treatment of antiviral, hepatoprotective enzyme, diuretic, protein and other nutritional support. The treatment group was treated with triple live viable Bifidobacterium tablets combined with lactulose oral solution on the basis of comprehensive treatment of liver protection. Hepatic encephalopathy, upper gastrointestinal bleeding, spontaneous peritonitis and disappearance of ascites were compared between the two groups. Results The incidence of hepatic encephalopathy, spontaneous peritonitis and ascites disappearance rate (12.9%, 24.2%, 79.0%) in the treatment group were significantly higher than those in the control group (32.2%, 45.8%, 61.0%), and the differences were statistically significant (P <0.05). There was no significant difference in the incidence of upper gastrointestinal bleeding between the two groups (P> 0.05). Conclusion Long-term application of probiotics can effectively improve the symptoms of cirrhosis, reduce the production of ascites and reduce the incidence of spontaneous peritonitis and hepatic encephalopathy, but the impact of upper gastrointestinal bleeding needs further study, this method and the general treatment was significantly Differences, is worth promoting the clinical treatment.